INAB · IN8bio Inc
United States · RS rating 23 · As of 2026-11-03
| Price | 0.95 USD |
|---|---|
| 1-day change | +4.4% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 10 / 58 / 21 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 6 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +3.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +63.3% |
| Market cap (USD) | $14.0M |